A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC)
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007260/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX
mesalamine once daily.
提供机构：
Vivli
创建时间：
2021-07-01
